Jenburkt Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE354A01013
  • NSEID: JENBURPH
  • BSEID: 524731
INR
899.35
-1.55 (-0.17%)
BSENSE

Nov 20

BSE+NSE Vol: 325

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 134395,
    "name": "Jenburkt Pharma",
    "stock_name": "Jenburkt Pharma",
    "full_name": "Jenburkt Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/jenburkt-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "899.35",
    "chg": -1.55,
    "chgp": "-0.17%",
    "dir": -1,
    "prev_price": "900.90",
    "mcapval": "392.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524731,
    "symbol": "JENBURPH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE354A01013",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "325 ",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/jenburkt-pharma-134395-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Jenburkt Pharmaceuticals Downgraded to Sell Amid Technical Weakness and Flat Financials",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/jenburkt-pharmaceuticals-downgraded-to-sell-amid-technical-weakness-and-flat-financials-4267487",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/JenburktPharmac_mojoScore_4267487.png",
        "date": "2026-11-19 08:03:05",
        "description": "Jenburkt Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell as of 18 Nov 2026, reflecting a deterioration in technical indicators despite an attractive valuation and stable financial metrics. The downgrade is driven primarily by a shift to bearish technical trends, while valuation metrics have improved, and financial performance remains flat. This comprehensive analysis explores the four key parameters influencing the rating change: Quality, Valuation, Financial Trend, and Technicals."
      },
      {
        "title": "Jenburkt Pharmaceuticals Upgraded to Hold on Improved Valuation and Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/jenburkt-pharmaceuticals-upgraded-to-hold-on-improved-valuation-and-technicals-4263105",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/JenburktPharmac_mojoScore_4263105.png",
        "date": "2026-11-16 08:03:11",
        "description": "Jenburkt Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold, driven primarily by improvements in technical indicators and a more attractive valuation profile. Despite recent flat financial performance and underwhelming returns over the past year, the company’s solid management efficiency and net-debt-free status underpin a cautiously optimistic outlook."
      },
      {
        "title": "Jenburkt Pharmaceuticals Gains 10.42%: 2 Key Factors Driving the Weekly Rally",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/jenburkt-pharmaceuticals-gains-1042-2-key-factors-driving-the-weekly-rally-4256290",
        "imagepath": "",
        "date": "2026-11-08 16:00:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Nov:</strong> Stock hits 52-week low at Rs.848.05</p>\n                    <p><strong>3 Nov:</strong> Sharp rebound with 4.65% gain to Rs.900.00</p>\n                    <p><strong>5 Nov:</strong> Valuation upgrade signals renewed price attractiveness</p>\n                    <p><strong>6 Nov:</strong> Week closes at Rs.943.00, up 10.42% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.854.00</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.943.00</div><div class=\"stat-ch..."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd: Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-4251078",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/JenburktPharmac_valuationdot_4251078.png",
        "date": "2026-11-05 08:00:20",
        "description": "Jenburkt Pharmaceuticals Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating. This change reflects a more compelling price point relative to its historical averages and peer group, despite the company’s mixed recent returns compared to the broader Sensex index."
      },
      {
        "title": "Five Consecutive Losses Push Jenburkt Pharmaceuticals Ltd to a New 52-Week Low",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-falls-to-52-week-low-of-rs-84835-4244930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/JenburktPharmac_priceRelatedfactors_4244930.png",
        "date": "2026-10-30 12:35:05",
        "description": "For the fifth straight session, Jenburkt Pharmaceuticals Ltd closed lower, breaching its 52-week low at Rs 848.35 on 30 Oct 2026. This decline comes amid a backdrop of underwhelming financial performance and persistent selling pressure, despite the broader market showing signs of resilience."
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd is Rated Sell by MarketsMOJO",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-by-marketsmojo-4243124",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/JenburktPharmac_mojoScore_4243124.png",
        "date": "2026-10-29 10:10:02",
        "description": "Jenburkt Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 7 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Five Consecutive Losses Push Jenburkt Pharmaceuticals Ltd to a New 52-Week Low",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-falls-to-52-week-low-of-rs8675-amid-market-downturn-4234167",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/JenburktPharmac_priceRelatedfactors_4234167.png",
        "date": "2026-10-22 13:40:04",
        "description": "For the fifth consecutive session, Jenburkt Pharmaceuticals Ltd has closed lower, hitting a fresh 52-week low of Rs 867.5 on 22 Oct 2026, marking a 6.01% decline over the last two days alone."
      },
      {
        "title": "Five Consecutive Losses Push Jenburkt Pharmaceuticals Ltd to a New 52-Week Low",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/jenburkt-pharmaceuticals-ltd-falls-to-52-week-low-amidst-declining-financial-metrics-4232188",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/JenburktPharmac_priceRelatedfactors_4232188.png",
        "date": "2026-10-21 10:35:05",
        "description": ""
      },
      {
        "title": "Jenburkt Pharmaceuticals Ltd is Rated Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/jenburkt-pharmaceuticals-ltd-is-rated-sell-4228421",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/JenburktPharmac_mojoScore_4228421.png",
        "date": "2026-10-17 10:10:05",
        "description": "Jenburkt Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 7 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 17 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      }
    ],
    "total": 62,
    "sid": "134395",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/jenburkt-pharmaceuticals-134395"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "04-Nov-2026",
      "details": "Newspaper Publication for standalone Unaudited financial results for the quarter and half year ended on 30th September 2026.",
      "source": "BSE"
    },
    {
      "caption": "Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011",
      "datetime": "04-Nov-2026",
      "details": "The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Counter Cyclical Investment Pvt Ltd",
      "source": "BSE"
    },
    {
      "caption": "Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026",
      "datetime": "03-Nov-2026",
      "details": "Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Jenburkt Pharmaceuticals Ltd has declared <strong>207%</strong> dividend, ex-date: 28 Aug 26",
          "dt": "2026-08-28",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Newspaper Publication

04-Nov-2026 | Source : BSE

Newspaper Publication for standalone Unaudited financial results for the quarter and half year ended on 30th September 2026.

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011

04-Nov-2026 | Source : BSE

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Counter Cyclical Investment Pvt Ltd

Standalone Unaudited Financial Results For The Quarter And Half Year Ended On 30Th September 2026

03-Nov-2026 | Source : BSE

Standalone Unaudited Financial Results for the quarter and half year ended on 30th September 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Jenburkt Pharmaceuticals Ltd has declared 207% dividend, ex-date: 28 Aug 26

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available